TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01046864
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
Study: NCT01488877
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: spironolactone 25 mg once daily
Study: NCT01095172
Drug: Mycophenylate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenylate mofetil 2g/day in divided doses
Study: NCT01095172
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.
Study: NCT01095172
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 0.3mg/kg on day 2, 0.25mg/kg on day 3, 0.2mg/kg on day 4 and 0.16mg/kg on day 5. On day 6 they will receive 5mg prednisolone, and on day 7 none.
Study: NCT01095172
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reducing dose of prednisolone over at least 6 months. Subsequent steroid maintenance or withdrawal will be at the discretion of the patient's clinician.
Study: NCT03163446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given as a single 2 hour iv infusion
Study: NCT00704379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: an inactive substance
Study: NCT00002551
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See arm assignments.
Study: NCT00002551
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See arm assignments.
Study: NCT02490774
Drug: BAY1007626
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)
Study: NCT03652818
Drug: Pre-Op Placebo 1
Normalized name: Sx Pre-Op Prep Pouch KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 will be administered 60 min prior to surgery.
Study: NCT03652818
Drug: Post-Op Placebo 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 will be administered post-operatively.
Study: NCT03652818
Drug: Post-Op Placebo 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 will be administered post-operatively.
Study: NCT03652818
Drug: Post-Op acetaminophen
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen will be administered Post-operatively.
Study: NCT03186313
Drug: Dactavira Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
Study: NCT03186313
Drug: Dactavira
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks
Study: NCT00524433
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00830219
Drug: Requip® 0.25 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 0.25 mg, single dose fed
Study: NCT01533870
Drug: NKTR-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 25 mg
Study: NCT04129697
Drug: Dexamethasone or Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: steroids
Study: NCT01940224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative administration of placebo
Study: NCT01052103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablets, twice daily: in the morning and in the evening, for 16 or 17 weeks.
Study: NCT01052103
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)
Study: NCT00184665
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01174732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, lactose inhalation carrier
Study: NCT00766363
Drug: EVP-6124 (0.1 mg/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVP-6124 was administered as one 0.1 mg capsule per day for 28 days.
Study: NCT00766363
Drug: EVP-6124 (0.3 mg/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVP-6124 was administered as one 0.3 mg capsule every day for 28 days.
Study: NCT00766363
Drug: EVP-6124 (1.0 mg/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVP-6124 was administered as one 1.0 mg capsule every day for 28 days.
Study: NCT00469573
Drug: 1. Optive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optive 15ml- (in the eye) Instill one drop twice daily in each eye
Study: NCT01912560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01912560
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients being treated with a stable dose of a statin prior to enrollment continue on their dosing regimen.
Study: NCT00094289
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02238808
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible participants will take 2 mg Estradiol 3 times daily for 7-14 days pre-surgery.
Study: NCT00239720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose of placebo given over 5 days of each 28 day cycle
Study: NCT02687854
Drug: Vitamin K antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed by treating physicians
Study: NCT04339049
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
Study: NCT00371332
Drug: Minocycline HCL Microspheres
Normalized name: minocycline HCl microspheres
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01383460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
Study: NCT02070510
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of SNAC is administered conconmitantly with victim compounds (days 15 and 22).
Study: NCT01107145
Drug: Artemether-Lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
Study: NCT04685993
Drug: LPCN 1144
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral LPCN 1144, total daily dose of 450 mg testosterone undecanoate administered as BID (225 mg testosterone undecanoate per dose).
Study: NCT01015014
Drug: AN3365
Approvals — FDA: no, EMA: no, PMDA: no
Description: LP, 600 mg vial; reconstituted in Normal Saline
Study: NCT01015014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride for injection
Study: NCT02231372
Drug: Berodual® Respimat® solution for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00596219
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib
Study: NCT00224263
Drug: Lingzhi (Ganoderma)
Normalized name: Ganoderma lucidum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01769677
Drug: 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
Study: NCT04474340
Drug: COVID-19 Convalscent Plasma
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: The source convalescent plasma is typically collected from individuals who have recovered from COVID-19 which contains antibodies titer against SARS-CoV-2 and is administered to patients with COVID-19. Donor eligibility criteria and qualification are based on American Accredited Blood Banks ( AABB) standards , including questionnaires and relevant transfusion-transmitted infections testing are performed. Furthermore, pathogen inactivation will be performed for each unit, CCP was only collected from individuals who meet all donor eligibility requirements (21 CFR 630.10 and 21 CFR 630.15). Donors must be found positive at a diagnostic test of nasopharyngeal swab at the time of illness and positive serological test for SARS-CoV-2 antibodies after recovery. All donors should have negative HLA antibodies.
Study: NCT00133406
Drug: glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4gm/kg; ie up to 8.3gm/d, with juice daily for 10 days
Study: NCT00133406
Drug: zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg twice weekly for 12 months
Study: NCT02548936
Drug: Ezetimibe+Simvastatin Drug Combination
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in Ezetimibe+Simvastatin Drug Combination group received simvastatin (10mg/day) + ezetimibe (20 mg/day) by oral administration for 12 month.
Study: NCT02900352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00028717
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00028717
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03387605
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo given 2 times daily for 72 hours
Study: NCT00061789
Drug: SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00421278
Drug: MK0633
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose MK0633 100mg po in the fed state administered during a 4-wk study.
Study: NCT00473005
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2 bid, Oral
Study: NCT02848287
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1\*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
Study: NCT01579019
Drug: RO5024048
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg po bid, 24 or 26 weeks
Study: NCT03351478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.
Study: NCT03351478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered as one capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day.
Study: NCT03289338
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5mg intravenous once a month for 3 months
Study: NCT03289338
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline intravenous once a month for 3 months
Study: NCT05105074
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 - Patients will not receive intrathecal morphine. Patients will receive only bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
Study: NCT01131182
Drug: Comparator: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription
Study: NCT00231790
Drug: MK-0634 50 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: one capsule orally, once daily in morning
Study: NCT00231790
Drug: MK-0634 125 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: one or three capsules orally, once daily in morning
Study: NCT00231790
Drug: Placebo for MK-0634
Approvals — FDA: no, EMA: no, PMDA: no
Description: one, two, three or four capsules orally once daily in morning
Study: NCT00785356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 capsules daily for 3 months
Study: NCT01820585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT02544451
Drug: LUM/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age).~LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older).
Study: NCT00687661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical placebo pill once weekly for 24 months
Study: NCT01119339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily
Study: NCT01119339
Drug: Reference
Normalized name: Loreal Preference Dark Auburn 4R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference, once daily
Study: NCT00434824
Drug: Oral testosterone undecanoate (Andriol)
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment for 12 months with oral TU 80 mg/d, oral TU 160 mg/d or oral TU 240 mg/d in divided doses
Study: NCT00434824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment for 12 months with placebo in divided doses
Study: NCT02150343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose every 4 weeks
Study: NCT00688558
Drug: JTT-705 600 mg and simvastatin 40 mg
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: * JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~* Simvastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, immediately following breakfast and/or assessments
Study: NCT00688558
Drug: Placebo and simvastatin 40 mg
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Simvastatin 40 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments
Study: NCT01290718
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900mg/m2 bid po on days 1-14 of each 3-week cycle
Study: NCT00473655
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg or 20mg
Study: NCT02685345
Drug: DS-8500a 25 mg
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02685345
Drug: DS-8500a 75 mg
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00915902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (corn oil), two 1-gram capsules taken twice daily for 8 weeks
Study: NCT01013974
Drug: GSK573719 250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strip 1 of the dry powder inhaler will contain GSK573719 250 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
Study: NCT01013974
Drug: GSK573719 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strip 1 of the dry powder inhaler will contain GSK573719 500 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
Study: NCT01013974
Drug: GSK573719 matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strip 1 and 2 of the dry powder inhaler will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
Study: NCT00651105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00927030
Drug: supplemental liquid melatonin
Normalized name: melatonin Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid melatonin will be given to the parent. There are 4 dose levels (1mg, 3mg, 6 mg, and 9mg)of melatonin that will be used at 3 week intervals. The child will start with 1mg and the dose will be increased at 3 week intervals until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. Once this goal is reached the child will stay on that dose through the remainder of the study.
Study: NCT00927030
Drug: flavored liquid or liquid supplemental melatonin
Normalized name: melatonin Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single blind for parents at initial 3-weeks dose period of 1 mg melatonin for 18 children where 3/18 children will receive placebo and 15/18 children will receive melatonin study drug. Each bottle will be labeled as: Flavored liquid placebo/or liquid melatonin. After this initial 3-week period all children will receive known melatonin in bottles that state this.
Study: NCT02478710
Drug: Aerosolized Tobramycin or Vancomycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin: 300 mg diluted in 5 mL of 0.9% normal saline q.12h. Vancomycin: 125 mg diluted in 5 mL 0.9% normal saline q.8h.
Study: NCT02987010
Drug: IDH305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocitrate Dehydrogenase 1 inhibitor
Study: NCT02478710
Drug: Aerosolized Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tobramycin: 5 ml 0.9% normal saline q. 12h. Placebo vancomycin: 5m 0.9% normal saline q. 8 hr.
Study: NCT03037073
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
Study: NCT01958905
Drug: Artemether-lumefantrine fixed combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01499485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily morning ABGA:~* If actual bicarbonate \> 26 mmol/L and pH \> 7.35: administration of enteral capsule of placebo.~* If actual bicarbonate \> 26 mmol/L and pH \<= 7.35, increase minute ventilation to reach pH \> 7.35 and then administer enteral capsule of placebo.~* If actual bicarbonate \<= 26 mmol/L: omit treatment that day.
Study: NCT04474483
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
Study: NCT00005998
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01307956
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01307956
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04611321
Drug: IBI318
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI318 will be given fixed dose via intravenous (IV) infusion on Day 1 of each 14-day cycle until disease progression or loss of clinical benefit.
Study: NCT02758782
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00296400
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01014533
Drug: Placebo dispensed to subject.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 11 days, (one pill at bedtime on nights 1 and 2, 2 pills at bedtime on nights 3-10, and 1 pill at bedtime on night 11, then D/C). They return to the Sleep Lab for polysomnography on nights 8 - 10 of medication so their sleep data can be compared.
Study: NCT03710330
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 110 ml normal saline IV just before skin incision
Study: NCT01204034
Drug: Inuvair
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
Study: NCT01663402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to alirocumab administered as a SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
Study: NCT01774591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
Study: NCT02679664
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg tablet of rosuvastatin
Study: NCT02786992
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01690663
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo